The Ion Smart and Resilient Cities Accelerator has announced its most recent cohort ahead of moving into the physical hub later this year. Photo by Natalie Harms/InnovationMap

The Ion Smart and Resilient Cities Accelerator has named the five companies participating in its latest cohort, which starts next week.

Launched in 2019, the programing for the accelerator and its member companies focus on addressing the needs and challenges the city of Houston and other major metros are facing — including climate change. The five selected companies will start the 12-week program next week with a goal of securing a pilot with the city.

"We're thrilled to kick-off Cohort 3," says Christine Galib, senior director of programs at The Ion, in a news release. "The ISRCA remains a core asset in The Ion's Programs portfolio, since it enables recurring collisions, connections, and collaborations among startups, stakeholders, and subject-matter experts."

The selected startups are:

  • Phase Filter/Kinetic Synergies: The university-born startup has created an automatically changing air filter that works with existing HVAC systems to lower cost and energy use as well as eliminate the annoying chore.
  • Frakktal: In an effort to create a circular economy, Frakktal repurposes and reuses discarded polymer materials from the greater Gulf Coast region to also use in the same region.
  • Moonshot Compost: The company collects food waste from Houston residents and businesses via curbside pickup and drop-off while also collects and provides data on each pickup.
  • Teratonix: Using radio frequency (RF) electromagnetic from radio /TV broadcast, cell phone tower, wifi routers, and more, Teratonix provides solutions to generate electricity.
  • Smart Watts:The company taps into smart meter sensors to enable a personalized energy monitoring dashboard that provides users with data to make better energy use decisions.

"The ISRCA Cohort 3 will highlight companies that focus on making sure Houston is here for generations to come," says Courtney Cogdill, program manager for The Accelerator Hub at The Ion, in the release. "By activating the Houston innovation ecosystem and showcasing Houston's talent, Cohort 3 will spotlight Houston as a city committed to sustainability."

The previous cohorts of the program focused on resilience and mobility in Cohort 1 and cleantech for Cohort 2.

"As the world-at-large expands their mobility with social distancing restrictions lifted, it's important cities and businesses review their sustainability practices and carbon footprint and continue to improve upon the progress that's been made," says Jan E. Odegard, interim executive director of The Ion, in the release. "The Ion is excited to empower entrepreneurs who will play a critical role in improving sustainability. With Houston and our diverse and innovative industries as a backdrop, The Ion is prepared to address the challenges sustainability will face in a post COVID-19 world."

The program will be housed in The Ion, a 266,000-square-foot mixed-use structure, which is expected to open within the next few months, along with the organization's other accelerator programs.

Learn more about The Ion's accelerators by streaming this recent Houston Innovators Podcast with Galib and Cogdill:

This week's roundup of Houston innovators includes Dorit Donoviel of TRISH, Anu Pansare of gBETA, and Christine Galib and Courtney Cogdill of The Ion. Courtesy photos

4 female Houston innovators to know this week

who's who

Editor's note: In the week's roundup of Houston innovators to know, I'm introducing you to four innovators across industries recently making headlines — from space tech to startup development organizations.

Dorit Donoviel, director of the Translational Research Institute for Space Health

NASA has renewed its support for Baylor College of Medicine's Translational Research Institute for Space Health. Libby Neder Photography

Baylor College of Medicine's Translational Research Institute for Space Health, known as TRISH, got the green light on a grant renewal from NASA, which will allow the organization to continue to conduct biomedical research geared at protecting astronauts in deep space through 2028. NASA opted to continue the partnership and now TRISH will receive additional funding of up to $134.6 million from 2022 to 2028.

"NASA has received outstanding value from our bold approach to sourcing and advancing space health research and technologies," institute director Dorit Donoviel, says in a statement. "We are proud to be NASA's partner in its human space exploration mission and to be supporting the research necessary to create new frontiers in healthcare that will benefit all humans." Click here to read more.

Anu Pansare, director of gBETA Houston

Anu Pansare has joined the local gBETA team. Photo via gbetastartups.com

Anu Pansare has a new gig. The Sugar Land-based consultant has over 20 years of experience working with the likes of Chevron, Schlumberger, and Accenture, as well as smaller startups. Pansare, who's also been involved with the Houston Angel Network, recently started as director of gBETA's Houston office.

As the main liaison between Houston and gener8tor's national network, Pansare will lead gBETA's third cohort — for which applications are open online — through its free 7-week program, which is designed to help participating companies gain early customer traction and develop key metrics that will make them more marketable for future investment. Click here to read more.

Christine Galib and Courtney Cogdill of The Ion

Christine Galib and Courtney Cogdill of The Ion join the Houston Innovators Podcast to discuss the four accelerator programs that are striving to advance Houston. Photos courtesy of The Ion

Courtney Cogdill, program director of the Accelerator Hub, and Christine Galib, senior director, at The Ion joined the Houston Innovators Podcast to discuss what all they are focused on across the business accelerator programs at the hub. Now more than ever, innovators are dedicating their careers to resilient technologies that can enhance the city's future. And this effort comes naturally to Houstonians, Galib says on the podcast.

"There is an ethos here that is one of roll up your sleeves, collaborate, and get to work. Get the work done, and have fun while you're doing it," she says on the show. "We all come together in a time of challenge, and we really show each other that we're not just individually resilient, we are collectively resilient." Click here to read more and stream the episode.

Christine Galib and Courtney Cogdill of The Ion join the Houston Innovators Podcast to discuss the four accelerator programs that are striving to advance Houston. Photos courtesy of The Ion

The Ion's accelerators are working to bring out the best in Houston — from resiliency to diversity

HOUSTON INNOVATORS PODCAST EPISODE 71

When you look at the business accelerator programs offered at The Ion, a rising innovation hub in Midtown, you see Houston represented. From energy and space tech to resiliency and diversity, the four accelerators intentionally cover what Houston is all about.

Courtney Cogdill, program director of the Accelerator Hub, and Christine Galib, senior director, at The Ion joined the Houston Innovators Podcast to discuss what all they are focused on across the business accelerator programs at the hub. Editor's note: This podcast was recorded ahead of the winter storm that affected the state of Texas this week.

Now more than ever, innovators are dedicating their careers to resilient technologies that can enhance the city's future. And this effort comes naturally to Houstonians, Galib says on the podcast.

"There is an ethos here that is one of roll up your sleeves, collaborate, and get to work. Get the work done, and have fun while you're doing it," she says on the show. "We all come together in a time of challenge, and we really show each other that we're not just individually resilient, we are collectively resilient."

Neither Galib nor Cogdill are from Houston — but each have observed the same resiliency among the city and its people.

"Houston really just picks itself back up by the bootstraps and just runs," Cogdill says.

But The Ion Smart and Resilient Cities Accelerator, launched in 2019, was only just the beginning for The Ion's Accelerator Hub. Last year, three more accelerator programs were announced — the Aerospace Innovation Hub for Minority Business Enterprises at The Ion, Austin-based DivInc's Accelerator, and the Rice Alliance Clean Energy Accelerator. These were made possible through a series of grants — a $1.4 million one from NASA to launch the ASCI-Hub and a $1.5 million one from Economic Development Administration.

Galib and Cogdill discuss each of the programs, as well as what they are excited for when The Ion opens later this year. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.